Samsung C&T FY 2025 Annual Report
Beta

Filed: March 12, 2026· period ending December 31, 2025DART

Samsung C&T annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 12, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

Samsung C&T FY 2025 Annual Report Analysis

Business Overview

• Bio segment revenue KRW 5.95T (+31% YoY), operating profit KRW 2.19T (+69% YoY) — now largest profit contributor, overtaking construction
• Samsung Biologics completed spin-off of Samsung Epis Holdings in Nov 2025, creating dedicated CDMO entity to eliminate biosimilar conflict-of-interest

Management Discussion & Analysis

• Bio segment revenue KRW 5.95T, up 30.9% YoY; operating profit KRW 2.19T, up KRW 895B — cited driver: Plant 4 full-scale operation driving production/sales volume increase
• Consolidated operating profit KRW 3.29T, up 10.4% YoY despite revenue declining 3.2% to KRW 40.74T; operating margin improved to 8.1% from 7.1%

Risk Factors

• Listed equity portfolio KRW 44.75T (FY2025 vs KRW 21.68T FY2024); 1% price move = KRW 332.5B OCI impact
• FX derivatives: 599 FX forward contracts at HQ alone across USD, EUR, JPY, CNY, KRW; group-wide total 1,150+ contracts across 13 subsidiaries

Samsung C&T FY 2025 Key Financial Metrics
DART

Total Assets

KRW 86.53T

▲ +39.6% YoY

Operating Cash Flow

KRW 3.02T

▼ -8.6% YoY

CapEx

KRW 1.74T

▲ +6.6% YoY

Source: KIFRS consolidated financial data from Samsung C&T annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding